Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited announced the application for quotation of 10,228,239 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially impacting the company’s liquidity and market presence by increasing the number of shares available to investors.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company’s primary products are centered around regenerative medicine, utilizing proprietary mesenchymal lineage adult stem cells to treat complex diseases.
YTD Price Performance: -0.91%
Average Trading Volume: 101,786
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.1B
See more data about MSB stock on TipRanks’ Stock Analysis page.
